Patient characteristics
. | Nonmyeloablative . | Myeloablative . | P . |
|---|---|---|---|
| No. of patients | 71 | 81 | — |
| Age, y | 58 (51-70) | 54 (51-66) | < .001 |
| Disease type with disease status at conditioning, no. (%) | .03* | ||
| AML | 21 (30) | 13 (16) | — |
| CR1 | 5 | 3 | — |
| CR2 | 4 | 1 | — |
| Relapse | 10 | 2 | — |
| Induction failure | 2 | 7 | — |
| ALL | 1 (1) | 3 (4) | — |
| CR1 | — | 1 | — |
| Relapse | 1 | 2 | — |
| CML | 9 (13) | 33 (41) | — |
| Early phase | 2 | 27 | — |
| Advanced phase | 7 | 6 | — |
| CLL | 13 (18) | 2 (2) | — |
| CR1 | — | 1 | — |
| Relapse | 13 | 1 | — |
| MDS | 15 (21) | 17 (21) | — |
| RA | 1 | — | — |
| RAEB | 14 | 17 | — |
| NHL | 9 (13) | 10 (12) | — |
| Low grade | 5 | 2 | — |
| Large cell | 4 | 8 | — |
| CMML | 3 (4) | — | — |
| Untreated | 3 | — | — |
| Other, no. (%) | — | 3 (4) | — |
| Type of transplant, no. (%) | — | — | .009 |
| MRD | 30 (42) | 52 (64) | — |
| URD | 41 (58) | 29 (36) | — |
| Transplant conditioning regimen, no. (%) | |||
| Flu/Bu | 71 (100) | 0 | — |
| CTX/TBI | 0 | 76 (94) | — |
| Bu/CTX | 0 | 5 (6) | — |
| GVHD prophylaxis, no. (%) | — | — | < .001 |
| Cyclosporine/prednisone | 16 (23) | 3 (4) | — |
| Tacrolimus/MTX | 55 (78) | 78 (96) | — |
| Stem cell source, no. (%) | < .0001 | ||
| PBSC | 66 (93) | 16 (20) | — |
| BM | 5 (7) | 65 (80) | — |
| Prior myeloablative transplant, no. (%) | 18 (25) | 3 (4) | < .0001 |
. | Nonmyeloablative . | Myeloablative . | P . |
|---|---|---|---|
| No. of patients | 71 | 81 | — |
| Age, y | 58 (51-70) | 54 (51-66) | < .001 |
| Disease type with disease status at conditioning, no. (%) | .03* | ||
| AML | 21 (30) | 13 (16) | — |
| CR1 | 5 | 3 | — |
| CR2 | 4 | 1 | — |
| Relapse | 10 | 2 | — |
| Induction failure | 2 | 7 | — |
| ALL | 1 (1) | 3 (4) | — |
| CR1 | — | 1 | — |
| Relapse | 1 | 2 | — |
| CML | 9 (13) | 33 (41) | — |
| Early phase | 2 | 27 | — |
| Advanced phase | 7 | 6 | — |
| CLL | 13 (18) | 2 (2) | — |
| CR1 | — | 1 | — |
| Relapse | 13 | 1 | — |
| MDS | 15 (21) | 17 (21) | — |
| RA | 1 | — | — |
| RAEB | 14 | 17 | — |
| NHL | 9 (13) | 10 (12) | — |
| Low grade | 5 | 2 | — |
| Large cell | 4 | 8 | — |
| CMML | 3 (4) | — | — |
| Untreated | 3 | — | — |
| Other, no. (%) | — | 3 (4) | — |
| Type of transplant, no. (%) | — | — | .009 |
| MRD | 30 (42) | 52 (64) | — |
| URD | 41 (58) | 29 (36) | — |
| Transplant conditioning regimen, no. (%) | |||
| Flu/Bu | 71 (100) | 0 | — |
| CTX/TBI | 0 | 76 (94) | — |
| Bu/CTX | 0 | 5 (6) | — |
| GVHD prophylaxis, no. (%) | — | — | < .001 |
| Cyclosporine/prednisone | 16 (23) | 3 (4) | — |
| Tacrolimus/MTX | 55 (78) | 78 (96) | — |
| Stem cell source, no. (%) | < .0001 | ||
| PBSC | 66 (93) | 16 (20) | — |
| BM | 5 (7) | 65 (80) | — |
| Prior myeloablative transplant, no. (%) | 18 (25) | 3 (4) | < .0001 |
— indicates not applicable; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory anemia with excess blasts; NHL, non-Hodgkin lymphoma; CMML, chronic myelomonocytic leukemia; MRD, matched related donor; URD, unrelated donor; Flu, fludarabine; Bu, busulfan; CTX, corticoste-roids; TBI, total body irradiation; MTX, methotrexate; BM, bone marrow.
AML/MDS/CML versus other disease.